Combined administration of barbourin–albumin and hirudin–albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta
-
Add time:08/02/2019 Source:sciencedirect.com
IntroductionThere are continuing needs for new antithrombotic agents and procedures. We hypothesized that the slowly cleared recombinant fusion proteins barbourin–albumin (BLAH6) and hirudin–albumin (HLAH6) would be effective in limiting fibrin(ogen) and/or platelet deposition in a rabbit model of arterial injury.
We also recommend Trading Suppliers and Manufacturers of hirudin HV3 (cas 134289-40-0). Pls Click Website Link as below: cas 134289-40-0 suppliers
Prev:Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes
Next:Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs08/03/2019
- Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes08/01/2019
- Potential use of hirudin in diabetic cataract: A study of galactose mediated human lens epithelial cells injury07/31/2019
- Investigation on recombinant hirudin via oral route07/30/2019
- Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: Role of recombinant hirudin variant III07/29/2019
- High cell density cultivation of recombinant Escherichia coli for hirudin variant 1 production07/28/2019
- Application of HPLC–ESI–ITMS in the quality control of carboxyterminal sequence confirmation for the recombinant DNA product Hirudin Variant 307/27/2019
- INHIBITION OF THROMBIN BY HIRUDIN GENETICALLY FUSED TO WILD-TYPE OR MUTANT ANTITHROMBIN07/26/2019
